The Patient Tearing Up My Waiting Room Is Why Cebranopadol Matters
Tris Pharma presents cebranopadol (TRN-228) dual NOP/MOP data at CPDD 2026. For patients with comorbid chronic pain and OUD,...
Lilly’s Bet on Abridge Exposes the Recruitment Handoff Nobody Wants to Own
Eli Lilly invested in Abridge's AI recruitment tool — but the real question is whether sites can operationalize patient...
Gene Therapy Just Delivered Dopamine Directly Into the Brain. Now Comes the Hard Part.
BBM-P002's Phase 1 data in 10 Parkinson's patients shows dual-target AAV gene therapy can restore dopamine synthesis. The FDA...
Selinexor Plus Ruxolitinib Meets Primary Endpoint in Myelofibrosis Trial
Selinexor plus ruxolitinib met its primary spleen response endpoint in myelofibrosis, with 49.8% achieving SVR35 versus 28% on ruxolitinib...
Atumelnant cuts androgen levels 67% while reducing glucocorticoid doses in CAH trial
Atumelnant cuts androgen levels 67% while reducing glucocorticoid doses to physiologic levels in CAH trial, advancing toward Phase 3.
Lilly’s pirtobrutinib reduces CLL progression risk 45% in Phase 3 trial
Lilly's pirtobrutinib reduces CLL progression risk 45% in Phase 3 trial, with triplet combination showing stronger outcomes in BTK...
Setmelanotide Shows 7-Point HQ-CT Reduction in Prader-Willi Syndrome Phase 2
Setmelanotide demonstrates 7-point HQ-CT reduction in Prader-Willi Syndrome Phase 2, with eight of ten patients showing clinically meaningful hyperphagia...
Mitapivat Met Hemoglobin Goal in Sickle Cell Phase 3, But Only 40.6% of Patients Responded
Mitapivat met hemoglobin goal in sickle cell Phase 3, with 40.6% of patients responding and showing significant transfusion burden...
Talquetamab Plus Darzalex Shows 30-Point Progression-Free Survival Gain in Multiple Myeloma
Talquetamab plus Darzalex achieved 81.3% progression-free survival at 24 months in Phase 3 multiple myeloma trial, a 30-point improvement...
What the PRAC’s June 2026 Valproate Meeting Highlights Actually Say About Paternal Exposure Risk
EMA's PRAC found paternal valproate exposure evidence "inconsistent" with causal NDD risk in offspring — but still recommended precautionary...